Perspective Therapeutics CATX
NYSE CATX
$2.98 -0.14 (-4.49%)
As of: Sep 9, 2026 · 3:59 PM EDT

Perspective Therapeutics (CATX) Construction in Progress (2011)

Perspective Therapeutics' (CATX) quarterly Construction in Progress came in at $123613.0 in Q2 2011.

Analysis

Perspective Therapeutics (CATX) Construction in Progress (2011) Analysis & Trends

Perspective Therapeutics has disclosed Construction in Progress across 1 years of filings, most recently posting $123613.0 for Q2 2011.

  • In Q2 2011, Construction in Progress changed N/A year-over-year to $123613.0; the TTM figure through Jun 2011 stood at $123613.0 (changed N/A YoY), while the FY2011 annual figure was $123613.0, changed N/A from the prior year.
  • Construction in Progress came in at $123613.0 for Q2 2011 at Perspective Therapeutics.
  • In the past five years, Construction in Progress ranged from a high of $123613.0 in Q2 2011 to a low of $123613.0 in Q2 2011.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Construction in Progress (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn -
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn -
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn -
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn -
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn -
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn -
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn -
10 Perspective Therapeutics 361.95 Mn 361.95 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2011 123,613.00